Thorleif Krarup proposed as new Chairman of Nutri Pharma ASA
(Thomson Reuters ONE) - This information is subject of the disclosure requirements acc. to §5-12 vphl(Norwegian Securities Trading Act)Thorleif Krarup to be proposed as new Chairman of the Board in ExtraordinaryShareholders Meeting to be held on February 12.With reference to stock exchange release of 22 February regarding ExtraordinaryShareholders Meeting on February 12, Nutri Pharma informs that the board ofNutri Pharma will propose to the shareholders in the extraordinary shareholdersmeeting of 12 February that Thorleif Krarup be elected as Chairman of the Boardof the company, conditioned upon and with effect from the completion of theBionor Immuno offer. Mr. Krarup, who is a Danish citizen residing in Denmark, isinter alia Deputy Chairman of the Boards of H. Lundbeck A/S (pharmaceuticals),Alk Abello A/S (allergytreatment/pharmaceuticals) and LFI A/S (investment company holding 72% of H.Lundbeck), Member of the Board of Group 4 Securicor Plc (security and cashservices, listed in London), Member of the Board Lundbeckfonden (foundation),and Member of the Board of The Crown Prince Frederik Fond (foundation). ThorleifKrarup has between 1992 and 2000 served as Group Chief Executive and Chairman ofthe Executive Board, Unidanmark and Unibank.He was Deputy Chief Executive Officer, Nordea AB, Stockholm in 2000-2001, GroupChief Executive and Chairman of the Executive Board, Nordea, 2001 - 2002, and in2002 - 2003 Senior Vice President Business development, NordeaAB, K?havn. From 2003 - 2009 he was a Board Member and Senior Advisorto Nordic Capital. He has since 2003 acted as a consultant to internationalinvestment companies and banks.Mr. Krarup intends to subscribe for shares in the contemplated Private Placementof minimum 50 MNOK for an amount equalling EUR 100.000. Further, Lars H?owner of 52 mill. shares in Nutri Pharma, has agreed to sell 3 million shares tomr Krarup at a price of NOK 3,10 per share (based on price of the NUT shares on21 February), conditioned upon the completion of the Bionor Immuno offer and thePrivate Placement. The 3 million shares will be subject to lock-up for 4 years,however so that 1 million shares can be sold in two years and an additional 1million shares after the third anniversary of the agreement.FOR FURTHER INFORMATION:Trond Syvertsen, CEO +47 23 01 09 60 / + 47 91 72 14 57[HUG#1376581]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 25.01.2010 - 02:36 Uhr
Sprache: Deutsch
News-ID 1009352
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Oslo
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 83 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Thorleif Krarup proposed as new Chairman of Nutri Pharma ASA
"
steht unter der journalistisch-redaktionellen Verantwortung von
Nutri Pharma (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
